Jul 13, 2015: Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
Jun 09, 2015: Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test Data at the 2015 Alzheimer's Association International Conference
May 20, 2015: Amarantus Reports First Quarter 2015 Financial Results and Business Overview
May 11, 2015: Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise Diagnostic for Multiple Sclerosis
Apr 07, 2015: Amarantus Reports 2014 Financial Results and Business Overview
Mar 23, 2015: Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015
Feb 23, 2015: Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Feb 18, 2015: Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test with Anavex Life Sciences
Jan 22, 2015: Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board
Jan 15, 2015: Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test Confirming Statistically Significant Markers for Alzheimer's
List of Tables
Amarantus Bioscience Holdings, Inc., Key Facts
Amarantus Bioscience Holdings, Inc. Pipeline Products and Clinical Trials Overview
Amarantus Bioscience Holdings, Inc. Pipeline Products by Equipment Type
Amarantus Bioscience Holdings, Inc. Pipeline Products by Indication
Amarantus Bioscience Holdings, Inc., Key Facts
Amarantus Bioscience Holdings, Inc., Major Products and Services
Amarantus Bioscience Holdings, Inc. Number of Pipeline Products by Development Stage
Amarantus Bioscience Holdings, Inc. Pipeline Products Summary by Development Stage
Biomarker-Based Diagnostic Assay - Alzheimer's Disease - Product Status
Amarantus BioScience Holdings, Inc. (Amarantus) is a biotechnology company that discovers and develops treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. The company offers diagnostics and therapeutics pipeline products. Its diagnostics include lymphocyte proliferation test, nuropro blood test and DNA sequencing (NGS) assay. Amarantus provides DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. The company’s therapeutics pipeline products include eltoprazine and mesencephalic-astrocyte-derived neurotrophic factor (MANF). It also offers phenoguard protein discovery engine platform. The company provides products for cell cycle dysfunction, endoplasmic reticulum stress, astrocyte-neuron biology, neurodegeneration and apoptosis. Amarantus is headquartered in San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Amarantus Bioscience Holdings, Inc.
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio